The FDA wants Amgen's Tavneos off the market. European regulators are investigating data-integrity concerns. And now, a pharma selling the drug in Japan is warning doctors against writing more prescriptions.
The FDA wants it off the market. European regulators are investigating data-integrity concerns. And now, a pharma company selling the drug in Japan is warning …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Switzerland monitors Japanese concerns over Tavneos drug
FDA seeks to withdraw avacopan approval over alleged data manipulation, false statements
Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug
Takeda slapped with $885M verdict in pay-for-delay antitrust case
Fierce Pharma Asia—BMS-Hengrui's $15B deal; Takeda’s 4.5K layoffs; Daiichi’s oncology ambition
Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Supreme Court declines to hear IRA challenges from Novo, AZ and more
Takeda found liable over antitrust plot to delay generic constipation drug
Regulatory tracker: Taiho's Inqovi widens its reach with FDA label expansion
Amgen has taken steps to update its Tavneos label amid an ongoing battle with the FDA.
Swissmedic closely monitoring international developments around the drug Tavneos.
The FDA has proposed to withdraw its approval of avacopan for ANCA-associated vasculitis, alleging that employees of the original…
The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron…
The committee reported cases of hematologic malignancies in a follicular lymphoma study dubbed SYMPHONY-1.
Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ordered the Japanese…
